Sun Pharma

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Sun Pharma has secured South Africa's approval for its generic semaglutide injection and plans to launch the once-weekly diabetes treatment in the coming days

The approval makes South Africa the second market after India where the drugmaker has secured regulatory clearance for its generic version of semaglutide

Pharma stock rally: Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences and Acutaas Chemicals surged up to 13% in Wednesday's trade.

Stocks to watch today: Maruti Suzuki, Uno Minda, BHEL, Torrent Pharma, Tata Power, IHCL, IDFC First Bank, Kalyan Jewellers, Premier Energies, RCF, RRP Defense, among others, will be in focus today

SBI is the only domestic bank to participate in the loan syndication

In the past month, the Nifty Pharma index outperformed the market by surging 7.4 per cent, as compared to 4.2 per cent rise in the Nifty 50.

In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.

Stocks to Watch today: RIL, RVNL, Voltas, Sun Pharma, TaMo, Bharat Forge, Dalmia Bharat are among other stocks that will be in focus today.

Sun ​Pharmaceutical Industries said ‌it will acquire 100% of ​Innovcare Lifesciences

Lupin, Intas Pharmaceuticals, Sun Pharma, MSN Laboratories, Natco Pharma, Zydus Life Sciences and Dr Reddy's Laboratories are some of the companies, the note said, that could potentially benefit.

Updated data from the CK-301-101 trial showed durable responses and manageable safety profile in patients with locally advanced cutaneous squamous cell carcinoma

Indian pharmaceutical companies are investing in specialty drugs, biosimilars and local manufacturing in the US despite a near 10 per cent fall in exports in FY26

In the March quarter, Sun Pharma reported net profit at ₹2,714 crore, as compared to ₹2,150 crore a year ago, up 26.2 per cent year-on-year (Y-o-Y)

Innovative medicines business crosses $1 billion milestone as company expands specialty pipeline and bets on Organon acquisition

India's largest drugmaker reported stronger-than-expected quarterly profit as growth in specialty medicines offset weakness in US sales

Q4FY26 company results: Firms including Hindalco Industries, Fortis Healthcare, Torrent Pharmaceuticals, Info Edge (India), and TTK Prestige are also to release their January-March earnings today

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Sun Pharma's acquisition of Organon as a transformational deal, doubling revenue to USD 12 billion with 30 per cent EBITDA margin, analysts.

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.